One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

Earlier this week, researchers presented data from the OPTIMUM (Optimization of Prostate Biopsy – Micro-Ultrasound Versus MRI) trial at the European Association of Urology Congress in Madrid, Spain.

Routine prostate cancer screenings save lives, yet some men still avoid them. However, making the process more streamlined increases the likelihood that men will get the tests they need to catch ...

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...

A multicenter clinical study in Austria has shown that a new, highly precise ultrasound approach can successfully target and treat early prostate cancer while preserving patients' quality of life.

Credit: Thinkstock By 5 years, 92% of men recovered pad-free continence, and 87% had preserved erectile function sufficient for penetration. MRI-guided whole-gland transurethral ultrasound ablation ...

New capability enables more precise prostate cancer detection, a major advancement for men's health across Idaho No one ...

MARKHAM, Ontario--(BUSINESS WIRE)--Exact Imaging today announced results from its OPTIMUM clinical trial demonstrating the non-inferiority of its ExactVu™ micro-ultrasound platform to MRI ...

Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...